يعرض 1 - 10 نتائج من 94 نتيجة بحث عن '"Enfermedad injerto contra huésped"', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 1
    كتاب
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    رسالة جامعية

    المؤلفون: Tarazona Jimenez, Alvaro Diego

    المساهمون: Orozco Oviedo, Carlos Alberto, Carvajal Estupiñán, Juan Fernando, Ochoa Vera, Miguel Enrique, Luna González, María Lucrecia, Ochoa Vera, Miguel Enrique 0000898465, Luna González, María Lucrecia 0001347422, Carvajal Estupiñán, Juan Fernando 0000150711, Luna González, María Lucrecia pLIVNZYAAAAJ, Ochoa Vera, Miguel Enrique 0000-0002-4552-3388, Luna González, María Lucrecia 0000-0003-2846-6868, Luna González, María Lucrecia 57216524897, Ochoa Vera, Miguel Enrique miguel-enrique-ochoa-vera, Luna González, María Lucrecia maría-lucrecia-luna-gonzález, Ochoa Vera, Miguel Enrique miguel-enrique-ochoa-vera-ab1468100/, Luna González, María Lucrecia maria-lucrecia-luna-gonzalez

    الوقت: 2009 a 2022

    وصف الملف: application/pdf

    العلاقة: Jones DS, Podolsky SH, Greene JA. The Burden of Disease and the Changing Task of Medicine. N Engl J Med. 2012 Jun 21;366(25):2333–8.; DANE. Estadísticas Vitales [Internet]. 2023 [cited 2023 Nov 23]. p. 48–52. Available from: https://www.dane.gov.co/files/investigaciones/poblacion/pre_estadisticasvitales_IIItrim_2022prTest. pdf; Fondo Colombiano de Enfermedades de Alto Costo C de AC (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2022; Bogotá, D. C. 2023. 2023. 1–268 p.; Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer. J Clin Oncol. 2013 Oct 10;31(29):3673–80.; Rifón JJ. Trasplante de progenitores hemopoyéticos Transplant of hemopoietic progenitors. Vol. 29, An. Sist. Sanit. Navar. 2006.; Moreno DF, Cid J. Enfermedad del injerto contra el receptor. Vol. 152, Med Clin (Barc). NLM (Medline); 2019. p. 22–8; Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000 Jun 15;95(12):3702–9.; Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb;21(2):266–74.; Messina C, Faraci M, de Fazio V, Dini G, Calò MP, Calore E. Prevention and treatment of acute GvHD. Bone Marrow Transplant. 2008 Jun 1;41(S2):S65–70.; Sharma SK. Acute Graft-Versus-Host Disease. In: Basics of Hematopoietic Stem Cell Transplant [Internet]. Singapore: Springer Nature Singapore; 2023. p. 573–608. Available from: https://link.springer.com/10.1007/978-981-19-5802-1_33Test; Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with f ludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456–64.; Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov 29;6(11):638–47.; Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016 Sep 21;37(36):2768801; Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC CardioOncol. 2021 Jun 1;3(2):250–9.; Pérez-Valencia AI, Cascos E, Carbonell-Ordeig S, Charry P, Gómez-Hernando M, Rodríguez-Lobato LG, et al. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv. 2023 May 23;7(10):2018–31.; Barnes D, Corp M, Loutit J, Neal F. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956;2:626–7; https://apolo.unab.edu.co/en/persons/miguel-enrique-ochoa-veraTest; http://hdl.handle.net/20.500.12749/25420Test; instname:Universidad Autónoma de Bucaramanga - UNAB; reponame:Repositorio Institucional UNAB; repourl:https://repository.unab.edu.coTest

  7. 7
    دورية أكاديمية
  8. 8
    رسالة جامعية
  9. 9
    رسالة جامعية
  10. 10
    دورية أكاديمية

    المساهمون: Ramos,TL, García-Guerrero,E, Caballero-Velázquez,T, Rodríguez-Gil,A, Caracuel-García,R, Nufer,M, Robles-Frías,MJ, Barbado,MV, Pérez-Simón,JA Instituto de Biomedicina de Sevilla (IBIS/CSIC), CIBERONC, Universidad de Sevilla, Sevilla, Spain. Ramos,TL Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA. Caballero-Velázquez,T, Pérez-Simón,JA Department of Hematology, University Hospital Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain., Takeda company (PCRS-2016-101751) partially supported the study, This work has been partially supported by the CIBERONC (CB16/12/00480), and TerCel 16/0011/0035. Spanish Association Against Cancer (AECC-POSTD18023LOPE) fellowship (TLR).

    وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

    العلاقة: https://www.nature.com/articles/s41409-021-01452-1Test; Ramos TL, García-Guerrero E, Caballero-Velázquez T, Rodríguez-Gil A, Caracuel-García R, Nufer M, et al. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. Bone Marrow Transplant. 2021 Dec;56(12):3049-3058; http://hdl.handle.net/10668/4301Test; PMC8636253